StocksMedium•13 November 2026•
1 min read
Eledon Pharmaceuticals Beats Q3 2026 Earnings Estimates
Key Facts
1Eledon Pharmaceuticals reported a GAAP EPS loss of $0.03, beating analyst estimates by $0.14.
2Cash, cash equivalents, and short-term investments totaled $69.7 million as of September 30, 2026.
Eledon Pharmaceuticals reported its financial results for the third quarter of 2026, posting a GAAP EPS loss of $0.03. According to Seeking Alpha, this performance beat analyst estimates by $0.14. The company’s cash, cash equivalents, and short-term investments totaled $69.7 million as of September 30, 2026.
ELDN closed at $2.37 on November 12, 2026, prior to the release of these quarterly figures. The updated cash position follows a period where the company's liquid assets stood at $133.3 million at the end of December 2025.